ProCE Banner Activity

MASH Matters: A Multidisciplinary Approach to Treatment and Monitoring

Clinical Thought

Learn how the rapidly evolving treatment landscape for metabolic dysfunction–associated steatohepatitis (MASH) now requires collaborative care with key specialists to ensure patients with MASH receive the personalized medicine they need to improve long-term outcomes.

Released: March 26, 2025

Expiration: March 25, 2026

Share

Provided by

Provided by Clinical Care Options, LLC in partnership with Practicing Clinicians Exchange, LLC

ProCE Banner

Supporters

Supported by an educational grant from Novo Nordisk.

Novo Nordisk

Partners

Practicing Clinicians Exchange

ProCE Banner

Disclosure

Primary Author

Mazen Noureddin, MD, MHSc: consultant/advisor/speaker: Akero, Alligos, Altimmune, AstraZeneca, Boehringer Ingelheim, Boston Pharma, Cytodyn, GlaxoSmithKline, Lilly, Madrigal, Merck, Novo Nordisk, Sagimet, Takeda, Terns; researcher: Akero, Allergan, Altimmune, Boehringer Ingelheim, Boston Pharma, Bristol Myers Squibb, Conatus, Corcept, Enanta, Galectin, Genfit, Gilead, GlaxoSmithKline, Kowa, Lilly, Madrigal, Merck, Novartis, Novo Nordisk, Rivus, Shire, Takeda, Terns, Viking, Zydus; individual publicly traded stocks/stock options: Akero, ChronWell, Cytodyn, Rivus Pharma.